Novel approaches including gene editing are creeping towards approval.
US clinical hold over Allogene’s entire pipeline has just been lifted.
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Novo moves into amyloidosis not long after Intellia made a splash here.
The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.